<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055898</url>
  </required_header>
  <id_info>
    <org_study_id>SAFFE2012</org_study_id>
    <secondary_id>2012-002969-35</secondary_id>
    <nct_id>NCT02055898</nct_id>
  </id_info>
  <brief_title>SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)</brief_title>
  <acronym>SAFFE</acronym>
  <official_title>Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to investigate whether enhancement of SWS, which is seen after a drug&#xD;
      called sodium oxybate, reduces the impact of sleep disruption in CFS on daytime function,&#xD;
      specifically sleepiness and mental performance. This is a safe and well-tolerated drug that&#xD;
      is licensed for excessive daytime sleepiness (EDS) and cataplexy associated with narcolepsy.&#xD;
&#xD;
      The investigators will study 12 patients diagnosed with CFS using international diagnostic&#xD;
      guidelines. The investigators will record overnight sleep with EEG (brainwave) measurement on&#xD;
      the 1st and 4th nights of a 4 night period during which sodium oxybate and placebo will be&#xD;
      taken nightly, and the investigators will measure next-day sleepiness, mental performance and&#xD;
      fatigue, and compare drug and placebo nights.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic fatigue syndrome (CFS), characterised by chronic disabling fatigue, sleep impairment&#xD;
      and other symptoms, is associated with neither a currently identifiable disease process nor&#xD;
      major psychiatric illness, and has an estimated prevalence in primary care of 1-2%. Sleep&#xD;
      impairment is common in nearly everyone with CFS, with both daytime sleepiness and&#xD;
      unrefreshing nighttime sleep reported, and consequent impact on daytime function. It may be&#xD;
      that fundamental regulatory processes that control sleep are disturbed in CFS, leading to&#xD;
      different effects on sleep and daytime symptoms depending on the subject's prior sleep,&#xD;
      daytime routine, medication and other factors. The investigators contacts with patient groups&#xD;
      have indicated that patients are generally confident that on days when their sleep is better&#xD;
      they perform better in the day. There is growing evidence that deep, slow wave sleep (SWS) is&#xD;
      altered in CFS, and this may suggest impairment of build up of sleep pressure during the day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EEG Slow Wave Activity During Sleep</measure>
    <time_frame>night 1</time_frame>
    <description>Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG Slow Wave Activity During Sleep</measure>
    <time_frame>night 4</time_frame>
    <description>Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daytime Sleepiness</measure>
    <time_frame>Day 2</time_frame>
    <description>time to fall asleep in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daytime Sleepiness</measure>
    <time_frame>Day 5</time_frame>
    <description>time to fall asleep in minutes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Chronic Fatigue Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo first, then sodium oxybate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single dose of placebo comparator (fresh potable water) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of sodium oxybate (3.0g as liquid) at bedtime for 4 nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium oxybate first, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single dose of sodium oxybate (3.0g as liquid) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of placebo comparator (fresh potable water) at bedtime for 4 nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Oxybate</intervention_name>
    <arm_group_label>Placebo first, then sodium oxybate</arm_group_label>
    <arm_group_label>Sodium oxybate first, then placebo</arm_group_label>
    <other_name>Xyrem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo (fresh potable water)</intervention_name>
    <arm_group_label>Placebo first, then sodium oxybate</arm_group_label>
    <arm_group_label>Sodium oxybate first, then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Meeting criteria for CFS according to both the revised CDC (Fukuda 5) and Canadian&#xD;
             diagnostic systems.&#xD;
&#xD;
          -  Aged 25-65.&#xD;
&#xD;
          -  Good grasp of the English language.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Taking any of the following medication: opioids, tramadol, phenytoin, valproate,&#xD;
             ethosuximide, benzodiazepines, zolpidem, zopiclone, zaleplon, antidepressant except&#xD;
             &lt;30mg amitriptyline, or any other medications likely to interact with sodium oxybate&#xD;
             or with sleep in the opinion of the investigators.&#xD;
&#xD;
          -  Current major psychiatric disorder.&#xD;
&#xD;
          -  Unusual sleep schedule; (bedtime routines that fall outside 9 p.m. to 10 a.m.; usual&#xD;
             time in bed &gt; 12 hours).&#xD;
&#xD;
          -  Pregnancy, lactation or being female and not using reliable contraception.&#xD;
&#xD;
          -  Relevant abnormal clinical findings at screening visit.&#xD;
&#xD;
          -  Taken alcohol in the 24 hours before each study visit or drugs of abuse in the week&#xD;
             before each study visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Nutt, DM FRCPsych</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellcome CRF, Imperial College, Hammersmith Campus</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>October 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic fatigue syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Sodium Oxybate</title>
          <description>7 patients with chronic fatigue syndrome</description>
        </group>
        <group group_id="P2">
          <title>Sodium Oxybate Then Placebo</title>
          <description>6 patients with chronic fatigue syndrome</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (at Least 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo First Then Sodium Oxybate</title>
          <description>7 Patients who meet criteria for CFS according to both the revised CDC (Fukuda 5) and Canadian diagnostic systems.</description>
        </group>
        <group group_id="B2">
          <title>Sodium Oxybate First Then Placebo</title>
          <description>6 Patients who meet criteria for CFS according to both the revised CDC (Fukuda 5) and Canadian diagnostic systems.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>EEG Slow Wave Activity During Sleep</title>
        <description>Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)</description>
        <time_frame>night 1</time_frame>
        <population>All participants who completed the study and whose recordings were adequate</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Oxybate</title>
            <description>All participants who completed the study and whose recordings were adequate, during the sodium oxybate period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants who completed the study, and whose recordings were adequate, during the placebo period</description>
          </group>
        </group_list>
        <measure>
          <title>EEG Slow Wave Activity During Sleep</title>
          <description>Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)</description>
          <population>All participants who completed the study and whose recordings were adequate</population>
          <units>uV^2/Hz</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00002653" spread="0.00000406"/>
                    <measurement group_id="O2" value="0.00002257" spread="0.00000339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EEG Slow Wave Activity During Sleep</title>
        <description>Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)</description>
        <time_frame>night 4</time_frame>
        <population>All participants who completed the study and whose recordings were adequate</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Oxybate</title>
            <description>All participants who completed the study and whose recordings were adequate, during the sodium oxybate period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants who completed the study, and whose recordings were adequate, during the placebo period</description>
          </group>
        </group_list>
        <measure>
          <title>EEG Slow Wave Activity During Sleep</title>
          <description>Total power in 0.5-4Hz band in microvolts squared per Hertz (uV^2/Hz)</description>
          <population>All participants who completed the study and whose recordings were adequate</population>
          <units>uV^2/Hz</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00003051" spread="0.00000492"/>
                    <measurement group_id="O2" value="0.00001759" spread="0.00000225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Daytime Sleepiness</title>
        <description>time to fall asleep in minutes</description>
        <time_frame>Day 2</time_frame>
        <population>All participants who completed the study and whose recordings were adequate</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Oxybate</title>
            <description>All participants who completed the study and whose recordings were adequate, during the sodium oxybate period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants who completed the study, and whose recordings were adequate, during the placebo period</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Sleepiness</title>
          <description>time to fall asleep in minutes</description>
          <population>All participants who completed the study and whose recordings were adequate</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.95" spread="0.773"/>
                    <measurement group_id="O2" value="15.3" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Daytime Sleepiness</title>
        <description>time to fall asleep in minutes</description>
        <time_frame>Day 5</time_frame>
        <population>All participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Oxybate</title>
            <description>All participants who completed the study and whose recordings were adequate, during the sodium oxybate period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All participants who completed the study, and whose recordings were adequate, during the placebo period</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Sleepiness</title>
          <description>time to fall asleep in minutes</description>
          <population>All participants who completed the study</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="0.9"/>
                    <measurement group_id="O2" value="17.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>All participants who received at least one dose of placebo</description>
        </group>
        <group group_id="E2">
          <title>Sodium Oxybate</title>
          <description>All participants who received at least one dose of sodium oxybate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Indigestion/upset stomach</sub_title>
                <description>including mild nausea</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>painful legs at night</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>unsteadiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>feels confused on waking</sub_title>
                <description>Brief period of disorientation on waking</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive sleep apnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>hay fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>central sleep apneas</sub_title>
                <description>as recorded with overnight polysomnography</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>itchy skin</sub_title>
                <description>mild itchiness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keith Boland</name_or_title>
      <organization>Imperial College London</organization>
      <email>k.boland@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

